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Abstract Hypertension affects 1–5% of children and
adolescents, and the incidence has been increasing in
association with obesity. However, secondary causes of
hypertension such as renal parenchymal diseases, congen-
ital abnormalities and renovascular disorders still remain
the leading cause of pediatric hypertension, particularly in
children under 12 years old. Other less common causes of
hypertension in children and adolescents, including immo-
bilization, burns, illicit and prescription drugs, dietary
supplements, genetic disorders, and tumors will be
addressed in this review.
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Introduction
Despite a recent increase in the diagnosis of pediatric
hypertension due to the proliferation of obesity, hyperten-
sion is relatively uncommon in the pediatric age group,
affecting 1–5% of children [1]. In contrast to adults,
hypertension in children is usually secondary to an
identifiable etiology, with the most common cause being
renal disease [2]. When evaluating a pediatric patient for
hypertension, it is reasonable to first consider the common
etiologies such as renal parenchymal diseases, congenital
abnormalities, and renovascular disorders. However, a
number of uncommon processes can also cause hyperten-
sion in the pediatric population. Each of these etiologies is
rare in and of itself, and the number of patients with
“unusual” causes will comprise less than 5% of all patients
with secondary hypertension. This review focuses on select
unusual etiologies (Table 1). Often, careful history and
consideration of the context or the presentation of hyper-
tension may be important clues to the diagnosis in these
less frequent processes.
Immobilization
Hypertension is a widely reported complication of immo-
bilization secondary to fractures, burns, or illness [3–8]. In
some studies, over half of children in skeletal traction
develop hypertension [3, 5, 7]. When this form of
hypertension occurs, it has been reported to manifest from
1 to 11 weeks following onset of immobilization [3, 6, 9,
10]. Although hypertension may develop in any patient
during prolonged immobilization, school-age and adoles-
cent males appear to be particularly at risk [3, 6, 9, 11]. The
pathophysiology of immobilization hypertension is unclear
and likely multifactorial. Two possible mechanisms that
have been investigated include hypercalcemia and in-
creased sympathetic activity.
Hypercalcemia
Immobilization due to fractures, burns, paralysis, or other
causes is known to induce marked changes in calcium
metabolism that may include hypercalcemia (>10.0 mg/dl),
hypercalciuria (urinary calcium/creatinine ratio >0.3), ele-
vated serum ionized calcium, and, if immobilization is
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mineral density [4, 12–17]. It has been demonstrated that
acute hypercalcemia during intravenous calcium infusion
increases blood pressure and peripheral vascular resistance
in both normotensive and hypertensive individuals [18, 19].
Whether or not alterations in calcium metabolism lead to
immobilization-induced hypertension is less clear. Several
case reports describe hypertension associated with marked
hypercalcemia, although in some of these reports, comorbid
conditions such as renal insufficiency may also have
contributed [9, 20]. However, larger studies on hyperten-
sion in immobilized children have found no significant
correlation between hypertension and hypercalcemia [3, 5].
Symptoms of hypercalcemia are nonspecific and include
nausea, vomiting, constipation, seizures, and behavioral
changes [11, 21]. If an immobilized patient develops
hypertension, it is reasonable to assess serum total and
ionized calcium, as ionized calcium may be elevated in
immobilized patients even with normal total calcium levels
[14].
The optimal treatment of immobilization-induced hyper-
calcemia has not been established. Increased fluid admin-
istration, loop diuretics, calcitonin, and bisphosphonates
have all been shown to decrease serum calcium in the short
term [16, 21, 22]. In the long run, however, increased
activity with weightbearing exercise is most effective in
inducing complete resolution of hypercalcemia and hyper-
tension [4, 9, 10, 14, 16].
Increased sympathetic activity
Patients in skeletal traction may develop hypertension
relatively early in their hospital course, usually 1–4 days
after immobilization [6, 23]. Increased sympathetic activity
has been implicated as a cause based on elevated concen-
trations of circulating catecholamines and increased activity
Table 1 Secondary causes of
hypertension
aEtiologies covered in this
review
Acute Chronic
Renal Renal
Acute poststreptococcal glomerulonephritis Chronic nephritis or kidney disease,
any cause
Hemolytic uremic syndrome Obstructive uropathy
Acute nephritis, any cause Polycystic kidney disease
Interstitial nephritis Multicystic dysplastic kidney
Acute kidney injury
Urinary tract obstruction
Vascular Vascular
Renal artery thrombosis Renal artery stenosis
Patent ductus arteriosus Aortic coarctation
Renal vein thrombosis Vasculitis
Williams syndrome
Ingestions Ingestions
Prescription medications
a Prescription medications
a
Over-the-counter medications Over-the-counter medications
Illicit drugs
a Illicit drugs
a
Herbal therapies
a Dietary supplements
a
Surgical/trauma/injury Endocrine/tumors
Immobilization/traction
a Pheochromocytoma
a
Hypercalcemia
a Renal trauma
a
Burns
a Neuroblastoma
a
Renal trauma Juxtaglomerular cell tumors
a
Abdominal wall defect closure
a Mesoblastic nephroma
Orthopedic limb lengthening
a Hyper-/hypothyroidism
Intravascular volume overload Congenital adrenal hyperplasia
Mineralocorticoid excess
Neurologic Genetic syndromes or inherited disorders
Pain Williams syndrome
a
Seizures Tuberous sclerosis
a
Neurofibromatosis
a
Apparent mineralocorticoid excess
Glucocorticoid remediable aldosteronism
Liddle’s syndrome
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One hypothesis has been that stretching of the sciatic nerve
activates a vasomotor response leading to hypertension, and
experimental stretching of the sciatic nerve in dogs
increases blood pressure [23].
In general, hypertension associated with traction is mild
to moderate and reversible, particularly with discontinua-
tion or modification of traction [3, 5, 7, 24, 25].
Immobilized patients should have blood pressures moni-
tored regularly. Volume status and the possibility of urinary
retention should be assessed, especially if the injury
involves the spinal cord. If traction modification is not
feasible, drug therapy with α-blockers, dihydropyridine
calcium-channel blockers, or direct vasodilators have been
effective [5, 6, 20, 25]. Further evaluation for other causes
of hypertension should be undertaken if blood pressure
does not normalize within 7–10 days after discontinuation
of immobilization.
Trauma and burns
Renal trauma
Posttraumatic hypertension can be separated temporally
into acute presentations and chronic complications. In the
acute setting, hypertension is a finding in up to 30% of
patients with blunt renal trauma [26–29]. However, it may
be difficult to determine whether the injured kidney itself is
the source of hypertension or if other factors are involved
for two closely related reasons. The first reason is that mild
to severe blunt trauma inc h i l d r e nf r o ma n yc a u s e
significantly elevates systolic blood pressure approximately
20 mmHg above the 95 percentile for age [30]. The second
reason is that the majority of children with renal injury
suffer multiple traumas, which may contribute to hyperten-
sion due to pain and anxiety [26, 27, 29, 31, 32].
The incidence of posttraumatic hypertension outside the
acute setting has been difficult to determine. Hypertension
was reported as a complication following renal trauma in
small series [27, 33]. However, larger, long-term follow-up
studies have not found an increased incidence of hyperten-
sion in patients with a history of renal trauma compared
with the general population [29, 34, 35]. Hutchison and
Nogrady found no hypertension in 77 children aged 3–
16 years who were followed for at least 2 years after renal
trauma despite documented scarring in 20 of the 77
children [36]. Similarly, Surana et al. found no hypertension
in 19 children followed for an average of 5.5 years after
renal trauma [37].
When posttraumatic hypertension occurs, the mechanisms
may include ischemia from arterial stenosis or occlusion;
parenchymalcompressionduetoperirenalhematoma,urinoma
or scar; and traumatic arteriovenous fistulae [28]. Initial
management of renal trauma is aimed at preserving renal
function and minimizing patient morbidity. Recent reports
demonstrated that nonoperative management of children with
renal injury of any severity preserves renal function and is not
associated with a higher complication rate [38–40].
Despite data showing that hypertension in children after
renal trauma is uncommon, hypertensive patients with a
history of renal trauma should undergo a focused evalua-
tion. Damaged kidneys in young children with or without
hypertension have been shown to demonstrate abnormal
growth, so ultrasound evaluation of renal size is reasonable
[36]. Other studies may include angiography to evaluate for
vascular stenosis, cortical imaging to evaluate scarring, and
renal vein renin assays. Therapy for posttraumatic hyper-
tension should be aimed at the RAAS.
Burns
Hypertension has been reported within 7–10 days of
hospitalization in up to half of children admitted for burns
and is more common in patients with greater than 20%
body surface area burns [41–43]. Popp et al. concluded that
hypertensive burn patients were more likely to develop
complications of encephalopathy and seizure compared
with normotensive patients and required careful blood
pressure monitoring [42].
The etiology of hypertension in burned children is not
entirely clear but seems in part to be due to a complex
neuroendocrine response. Increased activity of the RAAS
has been observed in both hypertensive and normotensive
pediatric burn patients and does not in itself account for
hypertension [43]. Popp et al. found the main difference
between hypertensive and normotensive burn patients to be
volume status, with hypertensive patients having received
overly aggressive fluid resuscitation [43]. Therefore, hyper-
volemia in a setting of active vasoconstriction from
neurohumoral causes appears to be the most likely etiology
of the hypertension [43].
Evaluation of burn patients with hypertension should
focus on adequate analgesia and conscientious fluid
management. Given the propensity of these patients to
have hypertensive encephalopathy and seizures, aggressive
treatment of high blood pressure is appropriate. Logical
therapies for hypertension in these patients include but are
not limited to diuretics, β-blockers, and angiotensin-
converting enzyme inhibitors (ACE-i).
Abdominal wall defects (AWD)
SurgicalclosureofAWDsuchasomphaloceleorgastroschisis
frequently results inhypertension and usually developswithin
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half of patients following closure of omphalocele compared
with only 20% following closure of gastroschisis [44]. The
etiology of the hypertension is unknown in these cases but is
hypothesized to be due to increased intra-abdominal pressure
leading to renovascular compression with ischemia and
activation of the RAAS. Hypertension following closure of
AWD is usually self-limited and lasts on average around
4 days for omphalocele patients and only 1 day for
gastroschisis patients [44]. Hypertension following AWD
closure is usually mild and self-limited, and its transient
nature often makes treatment unnecessary. Approximately
10% of AWD patents may develop persistent hypertension
requiring ongoing therapy. Whereas no specific recommen-
dations exist for treatment, calcium-channel blockers, β-
blockers, clonidine, and diuretics may be useful. If those
medications are not effective, judicious use of ACE-i has
been shown to be effective in neonatal hypertension. ACE-i
use should be carefully monitored for alterations in urine
output or renal function.
Drugs
Cocaine
Eight percent of high school seniors report using some form
of cocaine in their lifetime, and cocaine use was implicated
in 30% of all drug-related emergency room visits in 1999
[46, 47]. Following ingestion by intravenous, inhalation, or
enteral routes, cocaine stimulates central and peripheral α-
adrenergic receptors, inhibits catecholamine reuptake and
nitric oxide synthesis, and subsequently results in marked
vasoconstriction and hypertension [48–50]. Other physio-
logic effects of cocaine include increased heart rate and
temperature, dilated pupils, and erratic behavior [51]. The
duration of the effects of cocaine depend on the dose and
route of administration but is generally less than 1 h.
Therefore, outside of the emergency room setting, cocaine
is a rare cause of hypertension.
Diagnosis of cocaine-induced hypertension is based
primarily on clinical context, history, index of suspicion,
and physical exam. A urine toxicology screen may be sent,
but the results only indicate cocaine use within the last 3–
5 days and may not be available in time to assist in making
therapeutic decisions.
Therapy for cocaine toxicity should be aimed at reducing
cardiovascular risks of myocardial infarction, angina pecto-
ris, arrhythmias, and aortic dissection [48]. Alpha-blockers
such as phentolamine and prazosin are recommended [47].
Other effective agents include sodium nitroprusside and
nicardipine [48]. The use of β-blockers should be avoided
because their use can lead to unopposed α-adrenergic
activity and worsening of the hypertension [47, 48].
Methamphetamine and 3,4
methylenedioxymethamphetamine (MDMA or ecstasy)
Around 5% of high school seniors admit to using
methamphetamine and its synthetic cousin MDMA in their
lifetimes [52]. These drugs are taken recreationally for their
stimulant and hallucinogenic properties, with cardiovascu-
lar side effects of hypertension, increased heart rate, and
elevated temperature. The major cause of morbidity and
mortality related to methamphetamine use is intracerebral
hemorrhage associated with malignant hypertension, hy-
perthermia, and coagulopathy [48, 52–54]. Methamphet-
amines produce their effects by increasing catecholamine
release from presynaptic neurons and by weakly inhibiting
inactivation of the catecholamines by monoamine oxidase
[48]. In contrast to cocaine, methamphetamine is metabo-
lized more slowly, resulting in a longer duration of action
[48, 55].
Diagnosis and treatment of methamphetamine toxicity is
similar to that of cocaine. Therapy should be aimed at
safely reducing blood pressure. Dihydropyridine calcium-
channel blockers, sodium nitroprusside, and α-blockers
have all been recommended [48]. As with cocaine, β-
blockers are discouraged because of the risk of unopposed
alpha-adrenergic activity, leading to worsening of the
hypertension.
Prescription medications
Recreational use and abuse of prescription medications by
adolescents is increasing, with approximately 10% of 12th
graders reporting nonprescribed use of stimulants,
opioids, and sedatives in 2005 [56, 57]. The prescription
stimulants typically abused include dextroamphetamine
(Dexedrine and Adderall) and methylphenidate (Ritalin
and Concerta), which are prescribed for attention deficit/
hyperactivity disorder, narcolepsy, and depression unre-
sponsive to other medical therapies. These stimulants are
chemically related to amphetamines and have similar
physiologic effects, with hypertension, tachycardia, and
vasoconstriction.
Diagnosing hypertension due to prescription drug abuse
requires a high index of suspicion. A detailed history,
including medications used by family members, may be of
value. Therapy for hypertension due to prescription drug
abuse is similar to that of the illicit stimulants above [56].
Hypertension due to toxicity of illicit or prescription
drugs should be treated in the emergency room in
conjunction with the assistance of experienced toxicology
services.
2140 Pediatr Nephrol (2009) 24:2137–2146Herbal therapies
The use of herbal and complementary medicines is
widespread among the pediatric population, with more than
20% of children with acute or chronic illness reporting the
use of nonprescribed supplements [58, 59]. Herbal products
are used for many reasons among children and adolescents,
including therapy for acute and chronic illnesses, weight
loss, improvement in energy and athletic performance, and
because they are seen as more natural by caregivers [58, 60,
61]. A complete discussion of all herbal products with
adverse cardiovascular effects is outside the scope of this
article. However, two relatively common herbal supple-
ments with well-described adverse effects on blood pres-
sure are Ma Huang and licorice.
Ma Huang (ephedra)
Ephedra contains the alkaloids ephedrine and pseudoephed-
rine and is sold under a multitude of trade names. Ephedra
is used in the treatment of asthma, fever and chills, and
headaches and is found in a large number of weight-loss
formulations [60]. Ephedra is also used as a stimulant
commonly known as “herbal ecstasy” [62]. Ephedra is
usually consumed as a tea, although the formulation in
weight-loss and dietary supplements is usually tablet or
capsule form [60].
Following ingestion, ephedra is metabolized to norepi-
nephrine, leading to a number of cardiovascular side effects
including hypertension, tachycardia, arrhythmias, palpita-
tions, myocardial infarction, and stroke [53, 60, 63, 64]. The
diagnosis of ephedra toxicity may be difficult, as many
patients and caregivers may not consider ephedra-containing
products as medications and may not report its use.
Recommended therapy for acute ephedra toxicity is
similar to that for cocaine and other sympathomimetics.
Likewise, avoidance of β-blockers is prudent to prevent
unopposed α-adrenergic activity and worsening of hyper-
tension [53].
Licorice
Licorice is an extract of the root of Glycyrrhiza glabra and is
traditionally used for gastrointestinal complaints, bronchitis,
coughs, and hepatitis [65]. Licorice may be ingested as a tea
made form the plant root and may be found in candy,
chewing tobacco, and gum. The active ingredient of licorice
is glycyrrhizic acid which is subsequently metabolized to
glycyrrhetinic acid, an inhibitor of 11β-hydroxysteroid
dehydrogenase, the enzyme that normally catalyzes the
inactivation of cortisol to cortisone [60, 66–68]. In chronic
licorice ingestion, 11β-hydroxysteroid dehydrogenase inhi-
bition leads to increased levels of cortisol, activation of renal
mineralocorticoid receptors, and can lead to hypokalemia,
sodium, and water retention, hypertension, and heart failure
[60, 67]. In contrast to ephedra, hypertension with licorice
generally requires chronic use.
Licorice-induced hypertension is reversible upon discon-
tinuation of the compound, although inhibition of 11β-
hydroxysteroid dehydrogenase and elevations in blood
pressure may persist for up to 8 weeks [60, 66, 67, 69].
Hypertension from licorice responds to pharmacologic
therapy with spironolactone and eplerenone in animal
models [67, 70].
Genetic syndromes
Williams syndrome
Williams-Beuren syndrome, commonly referred to as
Williams syndrome, is clinically characterized by “elfin
facies”, mental retardation, infantile hypercalcemia, small
stature, supravalvular aortic stenosis, and coarctation and
stenosis of pulmonary and peripheral systemic arteries.
Hypertension can therefore occur in the neonatal period
associated with systemic hypercalcemia and later in child-
hood with the development of progressively worsening
peripheral vascular stenoses and vessel wall compliance.
The responsible molecular defect is a large, multigenic
deletion on the long arm of chromosome 7 (7q11.23) and
includes the gene for elastin, the major protein component
of the arterial wall [71]. Microscopic vascular pathology
includes thickening of the arterial wall, disorganization of
the elastic components, hypertrophy of smooth muscle
cells, and abnormal orientation of collagen bundles [72].
Mutation of the elastin gene and subsequent vascular
wall abnormalities are believed to be the cause of the
vascular stenoses and therefore the cause of hypertension in
up to 75% of patients. Recently, however, other genes
located within the large deletion fragment have been
associated with the development of hypertension. The
NCF1 gene encoding a subunit of nicotinamide adenosine
dinucleotide phosphate oxidase is responsible for the
generation of oxygen radicals and oxidative stress. When
included in the mutated sequence of patients with Williams
syndrome, the incidence of hypertension decreases, sug-
gesting that oxidative stress exacerbates the development of
hypertension in vessels with the molecular lesions of
Williams syndrome [73].
Up to two thirds of children and adolescents with
Williams syndrome will have hypertension due to renal
artery stenosis, aortic coarctation, and thoracoabdominal
aortic hypoplasia [73–75]. In most cases, the vascular
lesions are multiple, and isolated renal artery stenosis in
uncommon. Importantly, aortic stiffness is elevated and
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suggesting that intrinsic vascular abnormalities, probably
due to the structural arterial wall abnormalities, contribute
to the development of hypertension, even in the absence of
stenotic lesions [75].
Treatment of hypertension in patients with Williams
syndromeisdifficultatbest.Angioplasty isnot recommended
for stenotic lesions, as the majority of patients have multiple
lesions, and there are no reports of long-term success with
balloon procedures. The development of new lesions can be
expected over time. ACE-i are likely to help control blood
pressure in the presence of stenotic lesions but are associated
withtheriskofrenalinsufficiencywhenflowiscompromised.
Likewise, vasodilators have theoretical benefits, but the
increasing knowledge of intrinsic vascular wall pathology
and biochemical dysfunction perhaps explains the poor
response to most pharmacologic treatments.
Tuberous sclerosis (TSC)
TSC, an autosomal dominant process, is characterized by
hamartomas of the brain, retina, heart, kidneys, and skin.
Two genes may be mutated: TSC1, encoding hamartin, or
TSC2, encoding tuberin [76]. Two thirds of cases appear to
involve de novo mutations. In vivo, these two proteins form
a heterodimer complex that controls growth, differentiation,
and proliferation via inhibition of the target of rapamycin
(mTOR) cascade [76]. Loss of functionality of either
protein leads to activation of the proliferation cascade, but
how this leads to the differentiation abnormalities of
angiomyolipomas is unknown.
The usual renal lesion in TSC is multiple angio-
myolipomas—benign tumors composed of abnormal ves-
sels, immature smooth muscle cells, and fat cells—
occurring in 55–75% of patients [76]. The prevalence of
angiomyolipomas increases with age. Epithelial cysts can
occur as single entities or as a part of the recently described
TSC2/PKD1 contiguous gene syndrome, a more severe
phenotype occurring in 2–3% of patients [77].
Angiomyolipomas are rarely the cause of hypertension
but may occasionally result in compression of renal tissue or
damage from hemorrhage. Hypertension is more commonly
associated with epithelial cysts, especially in the more
fulminant form of TSC2/PKD1 [76, 78]. Renovascular
stenosis or aortic aneursyms occur rarely, and when seen,
the lesions fit within the pathologic spectrum of fibromus-
cular dysplasia [79]. Of important note, all patients with TSC
and hypertension should be evaluated for intracranial tubers,
a common finding and a cause of hypertension when
resulting in obstructive hydrocephalus.
The treatment of hypertension for patients with TSC is
nonspecific unless an offending lesion can be surgically
approached.
Neurofibromatosis
Neurofibromatosis type 1 (NF1) is a common autosomal
dominant disorder resulting from mesodermal and ectoder-
mal dysplasia. The normal NF1 gene product, neurofibro-
min, is a GTPase-activating protein that is ubiquitously
expressed and regulates proliferation by inhibiting ras
activity. Vascular lesions occur with an unknown frequency,
as most are asymptomatic, and abnormalities include intimal
proliferation, aneurysm formation, and arterial nodules.
Renal arterial involvement is the most common site of
symptomatic lesions and occurs in 1–2% of patients,
although abnormalities may occur throughout the vascular
tree [80]. Occasionally, compressive lesions from nearby
fibromas may cause hypertension.
Hypertension is common in patients with NF1, and its
prevalence increases with age. In children, the most
commonly identified secondary cause is renal artery
stenosis, whereas in adults, pheochromocytoma is more
common [80]. Of note, the majority of hypertensive
patients with NF1 do not have secondary hypertension,
although the frequency of vasculopathy and its unknown
pathophysiology make use of the term “essential” hyper-
tension for these patients inappropriate. When actively
investigated using ambulatory monitoring, the incidence of
hypertension in young people with NF1 is approximately
16–19% [81, 82].
Given the incidence of renovascular lesions and the
potentially catastrophic complications of pheochromocyto-
ma, it is generally recommended that these abnormalities be
ruled out in all hypertensive patients with NF1 [80]. For
renal artery lesions, angiography is preferred over magnetic
resonance imaging (MRI) due to its higher sensitivity in
localizing small lesions, and renal vein renin sampling is
recommended. Renal artery angioplasty for stenotic lesions
is less successful in NF1 patients than in those without the
disease but is a reasonable therapeutic strategy prior to more
dramatic surgical options [80, 81, 83]. Given the high
incidence of “essential” hypertension, it is possible that the
lower success rates with angioplasty represent hypertension
from more than one significant cause. The optimal pharma-
cologic management of hypertension in NF1 patients has not
been determined, but multiple options seem effective.
Tumors
Neuroblastoma
Neuroblastomas are composed of neuroectodermal cells
that arise from primitive sympathetic ganglion cells. During
normal development, these cells migrate to become the
adrenal medulla and parts of the sympathetic nervous
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solid neoplasms in childhood and are heterogenous, with
highly variable clinical courses and histopathology. They
most commonly arise in the adrenal gland but may also
occur in abdominal, thoracic, cervical, or pelvic sympa-
thetic ganglia. Hypertension may be a presenting feature of
neuroblastoma and is due to excess catecholamine produc-
tion and secretion by the mass. More commonly, mild
hypertension may be noted as a part of the evaluation of a
child with an abdominal mass, bone pain, or anemia [84].
The diagnosis is sealed with imaging, biopsy, and elevated
urinary vanillylmandelic acid/homovanillic acid (VMA/
HVA) levels without epinephrine/norepinephrine excess.
Treatment with sympathetic blockers or clonidine is usually
sufficient for hypertension management.
Pheochromocytoma
Pheochromocytoma, derived from cells of neural crest
origin, is the cause of hypertension in the pediatric age
group in less than 1% of cases. Although most commonly
sporadic, familial forms linked to Von-Hippel-Lindau
(VHL), multiple endocrine neoplasia (MEN2), NF1, and
succinate dehydrogenase B (SDHB) occur nearly twice as
commonly in children (39%) than in adults [85]. Given the
propensity for its association with inherited disorders,
pheochromocytoma is thought to result from a “two-hit”
phenomenon, especially in MEN2 and VHL. A recent study
evaluated pheochromocytomas from 14 children, all of
whom had significant chromosomal imbalances in tumor
DNA. Ten of the patients carried constitutive mutations for
VHL and SDHD [86].
Childhood pheochromocytoma is marked by sustained—
or, rarely—paroxysmal hypertension and often presents
with signs referable to central nervous system effects.
Compared with adults, children have a higher frequency of
bilateral or extra-adrenal tumors and a higher incidence of
malignancy (12%) [85]. The diagnosis remains complex in
pediatrics due to both the biochemical heterogeneity of the
tumors and the scarcity of pediatric normal values for
catecholamines and their derivatives, especially in the
young child. Plasma and timed urine epinephrine, norepi-
nephrine, VMA, metanephrine, and normetanephrine all
have merit, with urine norepinephrine, normetanephrine,
and VMA the most sensitive [85]. Plasma normetanephrine
appears to be the most sensitive plasma assay [87]. Given
the lack of standardized normal values for children, it
should be noted that growth and age result in higher daily
urine catecholamine excretions (expressed as μg/24 h).
Therefore, normal adult values may be elevated for children
[85]. Diagnosis through radiologic imaging is also likely to
involve multiple modalities. Ultrasound is a reasonable
screening tool, but MRI is utilized for more specific
presurgical imaging. Given the likelihood of multiple
lesions in children,
131I-metaiodobenzylguanidine (MIBG)
imaging is also recommended to localize small or unusually
placed tumors [85]. Treatment is classically described as
sequential α-adrenergic/β-adrenergic blockade with
phenoxybenzamine and propranolol, followed by surgical
excision of the tumor. Labetalol has been an effective
pharmaceutical agent in a number of cases, but it should be
noted that labetalol interferes with the efficacy of MIBG
scanning and can therefore complicate the evaluation [88].
Malignancy is difficult to predict based on macroscopic or
microscopic morphology of resected tumors, resulting in
the need for long-term follow-up for detection of metastases
or new masses [88]. Similarly, development of future
tumors is reasonably common, especially in the inherited
disorders, and long-term follow-up is required.
Juxtaglomerular cell tumors (JCT)
JCT are exceedingly rare, benign, renin-secreting tumors
that develop from the smooth muscle cells of the afferent
arterioles [89–93]. In addition to hypertension, patients with
JCT also commonly present with signs of hyperaldosteron-
ism, including hypokalemia, headache, polyuria, and
vomiting [89–93]. JCT have a peak incidence in the second
and third decades of life, with females affected slightly
more often than males, although there have been cases in
children as young as 5 years old [91, 92].
Diagnosis of JCT may require both laboratory and
imaging modalities. One larger study found that renal vein
renin did not lateralize in over half of the cases, although
computed tomography demonstrated renal masses in all
cases [92]. Surgery to remove all or part of the affected
kidney cures hypertension associated with JCT [89, 92, 93].
Therapy with ACE-i or dihydropyridine calcium-channel
blockers are effective in controlling blood pressure until
surgery can be performed [91, 92].
Summary
Evaluation of children and adolescents with hypertension
should focus on determining the etiology of the hyperten-
sion and initiating appropriate therapy. It is important to
note that patients with conditions associated with hyperten-
sion, such as immobilization, postoperative AWD, and
burns, should be closely monitored for development of
hypertension. In other settings such as the clinic or
emergency room, careful history and physical exam,
consideration of the context or presentation, and judicious
use of laboratory and imaging studies may provide
important clues to the diagnosis of rare causes of
hypertension.
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(Answers appear following the reference list.)
Immobilization
The association between hypertension and long-bone
traction and immobilization is most likely due to:
a. Intravascular volume expansion and sodium overload
b. Pain
c. Increased sympathetic activity and hypercalcemia
d. Renal arterial compression and ischemia
Trauma
The blood pressure pattern most commonly seen following
blunt trauma is:
a. Transient hypertension followed by normal blood
pressure long term
b. Normal blood pressure during the acute phase followed
by permanent hypertension
c. Severe hypertension acutely followed by slow resolution
over years
d. No clinically significant changes in blood pressure at
any point
Burns
Hypertension in burn patients should be aggressively
treated because of an increased incidence of:
a. Cardiac ischemia
b. Encephalopathy and seizures
c. Increased intracranial pressure and stroke
d. Electrolyte disarray and arrhythmias
Abdominal wall defects
Hypertension associated with an abdominal wall defect and
its repair is most commonly:
a. Mild and transient
b. Severe and transient
c. Mild and persistent
d. Severe and persistent
Stimulant medications
Which of the following is appropriately avoided in the
treatment of stimulant-induced hypertension?
a. Phentolamine
b. Propranolol
c. Nicardipine
d. Sodium nitroprusside
Genetic syndromes
The etiology of hypertension in William’s syndrome may
be:
a. Hypercalcemia
b. Vascular stenoses
c. Decreased vessel wall compliance
d. All of the above
Tumors
Accurate localization of pheochromocytomas usually
requires imaging with both:
a. MAG3 and MIBG
b. DMSA and MRI
c. MIBG and MRI
d. CT and glucoheptonate
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